ICER Report Drops Biogen’s Aduhelm $56k Price Tag by 95%, Notes Potentially Serious Side Effects
The Institute for Clinical and Economic Review (ICER) has published a revised report on Alzheimer’s disease drug Aduhelm. Although Biogen [...]
Clinerion and Datametrix Discuss Improving the Oncology Drug Development Pipeline Using RWE
Clinerion partnered with Datametrix to better understand how to develop synthetic control arms using real world evidence (RWE). Notably, researchers [...]
How Can RWE Advance Chronic Disease Research and Inform Decision-Makers?
Professor of Medicine and Epidemiology at Harvard Medical School and Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham [...]
Webinar on Value-Based Pricing Now Available On-Demand
Authors of a recently released book on drug pricing, The Right Price: A Value-Based Prescription for Drug Costs, hosted a webinar [...]
Updated FDA Guidance Recommends Inclusion of Patients with Incurable Cancers in Clinical Trials
The Food and Drug Administration (FDA) has issued draft guidance instructing clinical trial sponsors to include patients with incurable cancers [...]
IQVIA Infographic Details Applications of COVID-19 RWD
IQVIA is offering an infographic that illustrates the applications of COVID-19 real world data (RWD). Such data can be used [...]
ISMPP Launches Podcast Series on Medical Communications
The The International Society for Medical Publication Professionals (ISMPP) has launched a podcast series highlighting current trends related to medical [...]
Acting FDA Commissioner Janet Woodcock to Speak at STAT Breakthrough Science Summit
STAT News will hold its 2021 Breakthrough Science Summit on July 13th and 14th, 2021. Acting Commissioner of the U.S. [...]
Patient Engagement Strategies Include Core Compensation Principles
The International Society for Pharmacoeconomics and Outcomes Research recently published its May/July issue of its Value & Outcomes Spotlight journal [...]
ISPOR President Reflects on COVID-19 Challenges and Lasting Achievements
President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and Director and Partner at Boston Consulting Group Dr. [...]
Transitioning to Value-Based Care Requires Understanding Perceptions and Opening Up the Conversation to Diverse Stakeholders
Healthcare stakeholders hold different perceptions of value-based care, with some stakeholders associating “value” with sub-optimal care. A recent ISPOR article, [...]
Cigna’s New Shared Savings Program Offers $500 if Members Convert to Biosimilars as Billion Dollar Savings Loom
Cigna has launched a Shared Savings Program, aimed at reducing costs for its members by identifying alternative drugs offered at [...]
Upcoming ISPOR Webinar on NICE’s Modernized Data Handling Methods and 5-Year Strategy
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will hold a virtual event on July 15th at 11:00 AM [...]
Cures 2.0 Key Points Include New $6.5 Billion Federal Research Agency and Expanded RWD in Clinical Trials
Cures 2.0 was introduced on June 22nd. The proposed bipartisan legislation includes components that center on diversifying clinical trials and [...]
How Can Transparency Improve in RWD Studies?
Vice President and Global Head of Epidemiology for Johnson & Johnson Jesse Berlin shared his thoughts on real world evidence (RWE) [...]
Expanded Cures 2.0 Legislation Considers Patient Access and Broadened Use of RWD in Clinical Trials
A recent article, published by the Regulatory Affairs Professionals Society (RAPS), notes that a discussion draft meant to further the [...]
Biogen’s Aduhelm Brings Uncertainty and Concern Regarding Federal Budget
The FDA recently approved Biogen’s Aduhelm for use in patients with Alzheimer’s disease. However, its high price tag—$56,000—means that many [...]
Alzheimer’s Drug Could Equal Federal Government’s Spending on NASA
Biogen’s Aduhelm is exceedingly expensive at $56,000. If covered under Medicare, its cost could approach the federal government’s spending on [...]
HealthVerity’s IPGE Platform Overcomes RWD Challenges
Health Verity’s Identity, Privacy, Governance and Exchange (IPGE) platform takes on many of the challenges associated with real world data [...]
Register Today for Upcoming ISPOR Webinar on Using RWD to Improve Oncology Research and Patient Outcomes in China
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will host a webinar on June 29th, 2021, at 11:00 AM [...]
Biogen’s Aduhelm Unites Drug Pricing Advocates
Healthcare purchasers and employers have formed a coalition, EmployersRx, with the goal of convincing House and Senate members to enact [...]
University of Washington Professor Discusses HEOR and RWD Trends
University of Washington’s Anirban Basu discusses his thoughts on the role of real world data (RWD) in health economics and [...]
Biogen Considers Aduhelm Price Cut as Competing Alzheimer’s Drug Approved by FDA
Biogen and its partner Eisai released a statement regarding Alzheimer’s Drug Aduhelm, which is priced at $56,000 per year. The [...]
HealthVerity Webinar Highlights IPGE Platform in Processing RWD
HealthVerity’s Identity, Privacy, Governance and Exchange (IPGE) platform is streamlining the way real world data (RWD) is used to inform [...]
Is Prescription Drug Price Negotiation a Lasting Trend?
One proposed solution to high prescription drug prices is negotiating directly with manufacturers. Legislative changes allowing Medicare to carry out [...]